Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
BMJ Open|July 8, 2021
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trialBruno Francois, Simon Lambden, Sebastien Gibot, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 4, 2012
Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsisMarc Derive, Youcef Bouazza, Nacira Sennoun, et al.Cellular & Molecular Immunology|March 24, 2018
TREM-1 multimerization is essential for its activation on monocytes and neutrophilsKevin Carrasco, Amir Boufenzer, Lucie Jolly, et al.Scientific Reports|December 9, 2016
Effect of TREM-1 blockade and single nucleotide variants in experimental renal injury and kidney transplantationAlessandra Tammaro, Jesper Kers, Diba Emal, et al.International Journal of Cardiology|September 17, 2021
Plasma and genetic determinants of soluble TREM-1 and major adverse cardiovascular events in a prospective cohort of acute myocardial infarction patients. Results from the FAST-MI 2010 studyHafid Ait-Oufella, Mengyao Yu, Salma Kotti, et al.Cell Reports|February 13, 2024
THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1Julie Giraud, Domitille Chalopin, Eloïse Ramel, et al.Frontiers in Immunology|October 3, 2025
Tumor-dependent myeloid and lymphoid cell recruitment in genO-BRGSF-HIS mice: a novel tool for evaluating immunotherapiesGaëlle H Martin, Siham Hedir, Florent Creusat, et al.Intensive Care Medicine Experimental|August 13, 2023
Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patientsSébastien Gibot, Thomas Lafon, Laurent Jacquin, et al.Bioscience Reports|July 1, 2021
Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19Aline H de Nooijer, Inge Grondman, Simon Lambden, et al.Intensive Care Medicine|May 30, 2020
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trialBruno François, Xavier Wittebole, Ricard Ferrer, et al.Pageof 4